Syndromes Without a Name Bring Labs an Uphill Battle
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
From - Diagnostic Testing & Emerging Technologies
Samples collected from a mouth rinse can detect human papillomavirus (HPV) DNA. These easily collected samples might provide important monitoring information for…
From - Diagnostic Testing & Emerging Technologies
The U.S. Food and Drug Administration-cleared POC Afinion HbA1c Dx test (Alere Technologies a subsidiary of Abbott Laboratories) is accurate and…
From - Diagnostic Testing & Emerging Technologies
The Congo Red Dot (CRD) Paper Test is a simple, rapid, non-invasive tool that that may improve triage and the accuracy of preeclampsia (PE) diagnosis at the point of care, according to…
From - Diagnostic Testing & Emerging Technologies
Incomplete implementation of EGFR testing guidelines remains a problem in the realm of non-small cell lung cancer (NSCLC), according to a study published in…
From - Diagnostic Testing & Emerging Technologies
A new test could help clinicians objectively measure pain. According to a study published…
From - Diagnostic Testing & Emerging Technologies
Prenatal diagnostics have evolved from conventional cytogenetic analysis to increasingly chromosomal microarray analysis, within the last…
From - Diagnostic Testing & Emerging Technologies
Elevated donor-derived, cell-free DNA (ddcfDNA) in the 3 months post-lung transplant can identify clinically silent allograft injury and…
From - Diagnostic Testing & Emerging Technologies
Pharmacogenomic testing (PGx) provides clinically meaningful improvement in response and remission rates for difficult-to-treat depression patients over standard of care, according to…